Changes in bone mineral density after allogenic stem cell transplantation. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Joint Bone Spine Année : 2022

Changes in bone mineral density after allogenic stem cell transplantation.

Résumé

Objective Osteoporosis is a complication after allogenic stem cell transplantation (alloSCT). The purpose of this study was to assess changes in bone mineral density (BMD) 6 months and 3 years after alloSCT, as well as predictors of bone loss. Methods A longitudinal, prospective, single-center study was conducted at Lille University Hospital between 2005 and 2016. Clinical, biological, radiologic (thoracic and lumbar spine) and densitometric (DXA) assessments were carried out at baseline (pre-transplant), 6 months and 3 years. Patients with myeloma were not included. Results Two hundred and fifty-eight patients were included (144 men). Among them, 60.1% had leukemia and 65.8% of them, acute myeloid leukemia. At baseline, 6 months and 3 years, DXA-confirmed that osteoporosis was observed in 17%, 22.8% and 17.5% of the patients, respectively, mainly at the femoral neck. At baseline, 6 months and 3 years, 9 (8.5%), 53 (21.5%) and 38 (16.7%) patients, respectively, were receiving anti-osteoporotic treatment. From baseline to 6-month follow-up, BMD decreased significantly (p < 0.001) at the lumbar spine (−36 [95%CI; −51 to −20] mg/cm2 of hydroxyapatite), femoral neck (−43 [95%CI; −57 to −29] mg/cm2 of hydroxyapatite) and total hip (−53 [95%CI; −68 to −39] mg/cm2 of hydroxyapatite). From 6-month to 3-year follow-up, a significant increase in BMD was observed at the lumbar spine only (+31 [95%CI; 20 to 42] mg/cm2 of hydroxyapatite, p < 0.001). At all 3 sites, changes in BMD did not differ between patients treated or untreated by anti-osteoporotic treatment from 6-month to 3 year follow-up. Incident fractures were found in 4.1% and 5.7% of the patients at 6 months and 3 years, respectively. Between baseline and 6 months, bone loss at all 3 sites was associated with corticosteroid intake. At the total hip, 23.3% of the decrease in BMD from baseline to 6 months was due to an active hematological disease (p < 0.05), a bone marrow stem cells (p < 0.01) and a corticosteroid intake (p < 0.01). Conclusion Our study found evidence of bone fragility in alloSCT patients. Low BMD persisted at the hip 3 years after transplantation due to slower improvement at this site.

Dates et versions

hal-04424058 , version 1 (29-01-2024)

Identifiants

Citer

Diane Leguy, Leonardo Magro, Adeline Pierache, Valérie Coiteux, Ibrahim Yakoub-Agha, et al.. Changes in bone mineral density after allogenic stem cell transplantation.. Joint Bone Spine, 2022, Joint Bone Spine, 89 (5), pp.105373. ⟨10.1016/j.jbspin.2022.105373⟩. ⟨hal-04424058⟩
12 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More